BusinessAgile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017By Nasdaq OMXMay 6, 2017, 6:05 PM UTC
BusinessAgile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and GynecologistsBy Nasdaq OMXMay 3, 2017, 8:15 PM UTC
BusinessTrevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine MeetingBy Nasdaq OMXApr 6, 2017, 11:00 AM UTC
BusinessTrevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute PainBy Nasdaq OMXFeb 21, 2017, 12:00 PM UTC
BusinessTrevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute PainBy Nasdaq OMXJan 4, 2017, 12:01 PM UTC
BusinessTrevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute PainBy Nasdaq OMXJan 4, 2017, 12:01 PM UTC
